-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On April 19, Shanghai Pharmaceuticals issued an announcement stating that Xinya Minhang, its holding subsidiary, had received the "Notice of Approval of Drug Supplement Application" (notice) issued by the State Food and Drug Administration regarding enalapril maleate tablets (5mg, 10mg).
The announcement shows that enalapril maleate tablets are mainly suitable for primary hypertension, renovascular hypertension, heart failure at all levels, prevention of symptomatic heart failure, and prevention of coronary ischemia events in patients with left ventricular insufficiency.
As of the date of this announcement, the main manufacturers of the drug in China are Yangzijiang Pharmaceutical Group Jiangsu Pharmaceutical Co.